Latest Conference Articles

Gastric and Breast Cancer HER2 Testing Practices Show Potential in mCRC

Gastric and Breast Cancer HER2 Testing Practices Show Potential in mCRC

January 23rd 2023, 9:00pm

ASCO Gastrointestinal Cancers Symposium

Breast and gastric cancer algorithms are acceptable to use when identifying patients with colorectal cancer who may respond to tucatinib in combination with trastuzumab.

OS Improvements Seen With First-Line Liposomal Irinotecan/NALIRIFOX in Metastatic PDAC

OS Improvements Seen With First-Line Liposomal Irinotecan/NALIRIFOX in Metastatic PDAC

January 23rd 2023, 7:00pm

ASCO Gastrointestinal Cancers Symposium

Findings from the phase 3 NAPOLI 3 trial support the NALIRIFOX regimen as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma.

brPROPHET May Better Detect ctDNA and Identify MRD in Colorectal Cancer

brPROPHET May Better Detect ctDNA and Identify MRD in Colorectal Cancer

January 23rd 2023, 3:00pm

ASCO Gastrointestinal Cancers Symposium

According to initial data presented at the 2023 Gastrointestinal Cancers Symposium, the novel, personalized, tumor-informed brPROPHET technology was more sensitive in detecting molecular residual disease vs other assays.

ctDNA Serves as Biomarker for Early Response Assessment in Advanced CRC

ctDNA Serves as Biomarker for Early Response Assessment in Advanced CRC

January 23rd 2023, 2:00pm

ASCO Gastrointestinal Cancers Symposium

Compared with other tumor biomarkers, circulating tumor DNA may be ideal for early response assessment and have potential to enable use of adaptive clinical study designs in the future for patients with advanced colorectal cancer.

Promising Efficacy and Safety Signals Shown With Encorafenib Triplet in BRAF V600E+ mCRC

Promising Efficacy and Safety Signals Shown With Encorafenib Triplet in BRAF V600E+ mCRC

January 22nd 2023, 12:00pm

ASCO Gastrointestinal Cancers Symposium

The combination use of encorafenib plus cetuximab and chemotherapy appeared to be safe and effective in treating patients with BRAF V600E-mutant metastatic colorectal cancer.

Adding Veliparib or Pembrolizumab to Neoadjuvant Chemoradiation Not Beneficial for Locally Advanced Rectal Cancer

Adding Veliparib or Pembrolizumab to Neoadjuvant Chemoradiation Not Beneficial for Locally Advanced Rectal Cancer

January 21st 2023, 11:00pm

ASCO Gastrointestinal Cancers Symposium

NRG-GI002 helps to provide further total neoadjuvant therapy outcome data from multi-institutional national clinical trials that can benchmark and be used for future locally advanced rectal cancer outcomes, according to Thomas J. George, MD, FACP.

Adding Bevacizumab to Trifluridine/Tipiracil Boosts Survival, Disease Control Rate in mCRC

Adding Bevacizumab to Trifluridine/Tipiracil Boosts Survival, Disease Control Rate in mCRC

January 21st 2023, 10:34pm

ASCO Gastrointestinal Cancers Symposium

The SUNLIGHT study is the first phase 3 study in the setting of refractory metastatic colorectal cancer to demonstrate an improvement in overall survival vs an active control, according to Josep Tabernero, MD, PhD.

Antitumor Activity Seen With CD40-Directed SEA-CD40 Combo in Pancreatic Ductal Adenocarcinoma

Antitumor Activity Seen With CD40-Directed SEA-CD40 Combo in Pancreatic Ductal Adenocarcinoma

January 21st 2023, 2:30am

ASCO Gastrointestinal Cancers Symposium

SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab, showed early evidence of efficacy in patients with metastatic pancreatic ductal adenocarcinoma.

Treatment With or Without Bevacizumab Added to Atezolizumab and Chemotherapy Showed Benefit in BTC

Treatment With or Without Bevacizumab Added to Atezolizumab and Chemotherapy Showed Benefit in BTC

January 21st 2023, 2:28am

ASCO Gastrointestinal Cancers Symposium

Modest clinical benefit elicited with or without bevacizumab added to atezolizumab (Tecentriq) plus cisplatin/gemcitabine in biliary tract cancer.

Sorafenib in Combination with SBRT Extends Survival in Locally Advanced HCC

Sorafenib in Combination with SBRT Extends Survival in Locally Advanced HCC

January 21st 2023, 1:50am

ASCO Gastrointestinal Cancers Symposium

The phase 3 NRG/RTOG 1112 adds to the body of evidence for the role of external beam radiation, bringing SBRT to the armamentarium of treatment for patients with locally advanced hepatocelluar carcinoma, according to Laura Dawson, MD, FRCPC.